SK Biopharmaceuticals Maps Mid- to Long-Term Strategy to Build on Cenobamate Growth, Add New Drugs and Adopt AI
- Input
- 2026-11-18 09:54:55
- Updated
- 2026-11-18 09:54:55

SK Biopharmaceuticals said on the 18th that it presented this growth strategy at the Jefferies Global Healthcare Conference, being held in London, UK, from the 16th (local time) through the 19th. Attending for the fourth consecutive year, SK Biopharmaceuticals was the only Korean pharmaceutical and biotech company to give an in-person presentation.
At a presentation on the 17th, CEO Donghoon Lee outlined cenobamate’s growth and plans to expand the business. Cenobamate, marketed in the United States as Xcopri, had been prescribed to a cumulative total of more than 300,000 patients worldwide as of September this year.
The company is expanding the drug’s existing indication for partial-onset seizures in adults to include primary generalized tonic-clonic seizures and partial-onset seizures in children, while also developing new formulations such as an oral suspension. In overseas markets, it launched the product in China earlier this year, followed by South Korea and Japan, establishing a sales network in three Northeast Asian countries. It has also expanded its reach in Latin America to Peru, Chile, Brazil and other markets.
The company is also pursuing expansion of its central nervous system (CNS) business by securing new products. In August, SK Biopharmaceuticals in-licensed the epilepsy drug candidate Azetukalner (BHV-7000) from Biohaven. The candidate works by selectively activating Kv7.2/7.3 potassium ion channels, and is being studied in a Phase 2/3 clinical trial in adults with partial-onset seizures. Key results from the RISE3 trial, which has completed patient enrollment, are expected to be announced in the second half of this year.
The company is also broadening its R&D scope into oncology. It is identifying new therapeutic targets, focusing on next-generation technologies such as radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD).
The company also unveiled strategies to use AI for drug development and operational efficiency. Through its “AI-Native Operation” initiative—which includes AI-based candidate discovery, optimization of company-wide operations and the development of a patient disease-management platform—it plans to expand the use of AI from R&D to business operations.
President Donghoon Lee said, “Commercializing cenobamate in the United States has demonstrated our ability to develop new drugs ourselves and grow them in global markets. We will use AI and open innovation to strengthen our competitiveness in drug development and expand our business model connecting promising Asian assets with global markets.”
[email protected] Jung Sang-hee Reporter